- Home
- BXP vs PEN Comparison
BXP vs PEN Comparison
Compare BXP & PEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BXP | PEN |
|---|---|---|
| Founded | 1970 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.5B | 10.9B |
| IPO Year | 1997 | 2015 |
Fundamental Metrics
Financial Performance| Metric | BXP | PEN |
|---|---|---|
| Price | $71.45 | $313.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 16 |
| Target Price | $77.61 | ★ $311.25 |
| AVG Volume (30 Days) | ★ 1.2M | 493.7K |
| Earning Date | 01-27-2026 | 11-05-2025 |
| Dividend Yield | ★ 3.92% | N/A |
| EPS Growth | N/A | ★ 367.34 |
| EPS | N/A | ★ 4.14 |
| Revenue | ★ $3,425,025,000.00 | $1,333,798,000.00 |
| Revenue This Year | $3.60 | $16.77 |
| Revenue Next Year | $1.60 | $14.12 |
| P/E Ratio | ★ N/A | $75.40 |
| Revenue Growth | 2.42 | ★ 14.61 |
| 52 Week Low | $54.22 | $221.26 |
| 52 Week High | $81.59 | $315.01 |
Technical Indicators
Market Signals| Indicator | BXP | PEN |
|---|---|---|
| Relative Strength Index (RSI) | 53.18 | 67.84 |
| Support Level | $68.04 | $286.75 |
| Resistance Level | $72.50 | $303.00 |
| Average True Range (ATR) | 1.44 | 8.12 |
| MACD | 0.13 | 0.95 |
| Stochastic Oscillator | 67.84 | 89.28 |
Price Performance
Historical ComparisonAbout BXP Boston Properties Inc.
BXP Inc. owns over 180 properties consisting of approximately 53 million rentable square feet of space. The portfolio is dominated by office buildings and is spread across major cities such as New York, Boston, San Francisco, Los Angeles, Seattle, and the Washington, D.C., region. The real estate investment trust also owns limited retail, hotel, and residential properties.
About PEN Penumbra Inc.
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.